“CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has obtained marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg™, its pegylated filgrastim biosimilar version,” according to a stock exchange filing.
Also Read: Five medium-term triggers that can contribute to a 35% upside in Aurobindo Pharma shares
This marks CuraTeQ’s third biosimilar approval from the MHRA, following the authorisations of Bevqolva in December 2024 and Zefylti in May 2025. Dyrupeg, used to reduce the risk of infection in patients undergoing chemotherapy, had earlier secured marketing authorisation from the European Commission in April 2025.
Fourth quarter
Aurobindo Pharma reported an 11% year-on-year rise in consolidated revenue at ₹8,382.1 crore for the March quarter, broadly in line with Street estimates. Growth was driven by a 13.5% YoY increase in US formulation sales and a 17.2% jump in European formulations, with both geographies contributing significantly to the company’s top line.
Also Read: Aurobindo Pharma shares get an upgrade after a 25% drop from peak on attractive valuations
The firm’s net profit for the quarter stood at ₹902.8 crore, slightly down from ₹907.4 crore a year ago, and below the CNBC-TV18 poll estimate of ₹1,041.5 crore. EBITDA grew 7.1% YoY to ₹1,792 crore, also missing the expected ₹1,852.4 crore. The EBITDA margin came in at 21.38%, slightly lower than both the previous year and poll projections.
Shares of Aurobindo Pharma Ltd ended at ₹1,106.40, up by ₹6.65, or 0.60%, on the BSE.
(Edited by : Shoma Bhattacharjee)
